The many faces of Janus kinase

Biochemical Pharmacology

Volumn 83, Issue 9, 2012, Pages 1136-1145

  Seavey, Matthew M ^a   Dobrzanski, Pawel ^a  

^a CEPHALON INC   (United States)

Author keywords

Autoimmunity; Cancer; Inflammation; Janus kinase; Small molecule

Indexed keywords

AC 430; AEG 41174; AZD 1480; BMS 911543; CEP 33779; CYT 387; DISEASE MODIFYING ANTIRHEUMATIC DRUG; DOXORUBICIN; INCB 28050; JANUS KINASE; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE 2 INHIBITOR; JANUS KINASE 3; JANUS KINASE INHIBITOR; LY 2784544; LY 3009104; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; ONX 0803; PROTEIN TYROSINE KINASE INHIBITOR; RUXOLITINIB; SB 1317; SB 1518; SB 1578; STAT3 PROTEIN; STAT5 PROTEIN; TG 101348; TOFACITINIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; XL 019;

ADJUVANT THERAPY; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER THERAPY; CARCINOGENESIS; CARDIOVASCULAR DISEASE; CELL METABOLISM; CELL PROLIFERATION; CELL TRANSFORMATION; COLITIS; COLORECTAL CANCER; CROHN DISEASE; DIABETES MELLITUS; DRUG APPROVAL; DRUG CYTOTOXICITY; DRUG INDICATION; DRUG MECHANISM; DRUG RESEARCH; DRUG TARGETING; ECZEMA; ENTERITIS; ENZYME ACTIVATION; ENZYME INHIBITION; EPIGENETICS; GENE AMPLIFICATION; GENE EXPRESSION REGULATION; GENE MUTATION; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNE SYSTEM; IMMUNOTHERAPY; INFLAMMATION; MALARIA; METABOLIC DISORDER; MOLECULARLY TARGETED THERAPY; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDER; NEOPLASM; NERVE REGENERATION; NEUROLOGIC DISEASE; NEUROPATHIC PAIN; NEUROPROTECTION; NONHUMAN; PAIN; PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SOLID TUMOR; SYSTEMIC LUPUS ERYTHEMATOSUS; TUMOR CELL; ULCERATIVE COLITIS;

EID: 84858078774     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2011.12.024     Document Type: Note

References (112)

1. D. Ungureanu, J. Wu, T. Pekkala, Y. Niranjan, C. Young, and O.N. Jensen The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling Nat Struct Mol Biol 18 9 2011 971 976
2. A. Sanz, D. Ungureanu, T. Pekkala, R. Ruijtenbeek, I.P. Touw, and R. Hilhorst Analysis of Jak2 catalytic function by peptide microarrays: the role of the JH2 domain and V617F mutation PLoS ONE 6 4 2011 e18522
3. M.A. Dawson, A.J. Bannister, B. Gottgens, S.D. Foster, T. Bartke, and A.R. Green JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin Nature 461 7265 2009 819 822
4. L. Rui, N.C. Emre, M.J. Kruhlak, H.J. Chung, C. Steidl, and G. Slack Cooperative epigenetic modulation by cancer amplicon genes Cancer Cell 18 6 2010 590 605
5. H. Yu, and R. Jove The STATs of cancer - new molecular targets come of age Nat Rev Cancer 4 2 2004 97 105
6. H. Yu, D. Pardoll, and R. Jove STATs in cancer inflammation and immunity: a leading role for STAT3 Nat Rev Cancer 9 11 2009 798 809
7. M. Hedvat, D. Huszar, A. Herrmann, J.M. Gozgit, A. Schroeder, and A. Sheehy The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors Cancer Cell 16 6 2009 487 497
8. J. Bromberg, and T.C. Wang Inflammation and cancer: IL-6 and STAT3 complete the link Cancer Cell 15 2 2009 79 80
9. S.I. Grivennikov, F.R. Greten, and M. Karin Immunity, inflammation, and cancer Cell 140 6 2010 883 899
10. T. Putoczki, and M. Ernst More than a sidekick: the IL-6 family cytokine IL-11 links inflammation to cancer J Leukoc Biol 88 6 2010 1109 1117
11. N. Li, S.I. Grivennikov, and M. Karin The unholy trinity: inflammation, cytokines, and STAT3 shape the cancer microenvironment Cancer Cell 19 4 2011 429 431
12. I. Melzner, M.A. Weniger, A.J. Bucur, S. Bruderlein, K. Dorsch, and C. Hasel Biallelic deletion within 16p13.13 including SOCS-1 in Karpas1106P mediastinal B-cell lymphoma line is associated with delayed degradation of JAK2 protein Int J Cancer 118 8 2006 1941 1944
13. T. Oka, M. Ouchida, M. Koyama, Y. Ogama, S. Takada, and Y. Nakatani Gene silencing of the tyrosine phosphatase SHP1 gene by aberrant methylation in leukemias/lymphomas Cancer Res 62 22 2002 6390 6394
14. J. Reddy, N. Shivapurkar, T. Takahashi, G. Parikh, V. Stastny, and C. Echebiri Differential methylation of genes that regulate cytokine signaling in lymphoid and hematopoietic tumors Oncogene 24 4 2005 732 736
15. A. Saudemont, A. Hamrouni, P. Marchetti, J. Liu, N. Jouy, and D. Hetuin Dormant tumor cells develop cross-resistance to apoptosis induced by CTLs or imatinib mesylate via methylation of suppressor of cytokine signaling 1 Cancer Res 67 9 2007 4491 4498
16. H. Yoshikawa, K. Matsubara, G.S. Qian, P. Jackson, J.D. Groopman, and J.E. Manning SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity Nat Genet 28 1 2001 29 35
17. K.J. Morgan, and D.G. Gilliland A role for JAK2 mutations in myeloproliferative diseases Annu Rev Med 59 2008 213 222
18. R.L. Levine, and D.G. Gilliland JAK-2 mutations and their relevance to myeloproliferative disease Curr Opin Hematol 14 1 2007 43 47
19. A. Quintas-Cardama, H. Kantarjian, J. Cortes, and S. Verstovsek Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond Nat Rev Drug Discov 10 2 2011 127 140
20. C.G. Mullighan, J. Zhang, R.C. Harvey, J.R. Collins-Underwood, B.A. Schulman, and L.A. Phillips JAK mutations in high-risk childhood acute lymphoblastic leukemia Proc Natl Acad Sci USA 106 23 2009 9414 9418
21. J.D. Roll, and G.W. Reuther CRLF2 and JAK2 in B-progenitor acute lymphoblastic leukemia: a novel association in oncogenesis Cancer Res 70 19 2010 7347 7352
22. G. Lenz, G.W. Wright, N.C. Emre, H. Kohlhammer, S.S. Dave, and R.E. Davis Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways Proc Natl Acad Sci USA 105 36 2008 13520 13525
23. M.R. Green, S. Monti, S.J. Rodig, P. Juszczynski, T. Currie, and E. O'Donnell Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma Blood 116 17 2010 3268 3277
24. J. Galon, A. Costes, F. Sanchez-Cabo, A. Kirilovsky, B. Mlecnik, and C. Lagorce-Pages Type, density, and location of immune cells within human colorectal tumors predict clinical outcome Science 313 5795 2006 1960 1964
25. H. Yu, M. Kortylewski, and D. Pardoll Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment Nat Rev Immunol 7 1 2007 41 51
26. M. Kujawski, M. Kortylewski, H. Lee, A. Herrmann, H. Kay, and H. Yu Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice J Clin Invest 118 10 2008 3367 3377
27. M. Kortylewski, H. Xin, M. Kujawski, H. Lee, Y. Liu, and T. Harris Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment Cancer Cell 15 2 2009 114 123
28. M. Kortylewski, M. Kujawski, T. Wang, S. Wei, S. Zhang, and S. Pilon-Thomas Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity Nat Med 11 12 2005 1314 1321
29. J. Hermann, S. Gruber, J.B. Neufeld, P. Grundtner, M. Graninger, and W.B. Graninger IL10R1 loss-of-function alleles in rheumatoid arthritis and systemic lupus erythematosus Clin Exp Rheumatol 27 4 2009 603 608
30. M. Kujawski, C. Zhang, A. Herrmann, K. Reckamp, A. Scuto, and M. Jensen Targeting STAT3 in adoptively transferred T cells promotes their in vivo expansion and antitumor effects Cancer Res 70 23 2010 9599 9610
31. A.J. Trimboli, C.Z. Cantemir-Stone, F. Li, J.A. Wallace, A. Merchant, and N. Creasap Pten in stromal fibroblasts suppresses mammary epithelial tumours Nature 461 7267 2009 1084 1091
32. J. Condeelis, and J.W. Pollard Macrophages: obligate partners for tumor cell migration, invasion, and metastasis Cell 124 2 2006 263 266
33. C. Murdoch, M. Muthana, S.B. Coffelt, and C.E. Lewis The role of myeloid cells in the promotion of tumour angiogenesis Nat Rev Cancer 8 8 2008 618 631
34. D.G. DeNardo, J.B. Barreto, P. Andreu, L. Vasquez, D. Tawfik, and N. Kolhatkar CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages Cancer Cell 16 2 2009 91 102
35. H.E. Kohrt, N. Nouri, K. Nowels, D. Johnson, S. Holmes, and P.P. Lee Profile of immune cells in axillary lymph nodes predicts disease-free survival in breast cancer PLoS Med 2 9 2005 e284
36. D. Iliopoulos, H.A. Hirsch, and K. Struhl An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation Cell 139 4 2009 693 706
37. S. Grivennikov, E. Karin, J. Terzic, D. Mucida, G.Y. Yu, and S. Vallabhapurapu IL-6, Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer Cancer Cell 15 2 2009 103 113
38. D. Hanahan, and R.A. Weinberg Hallmarks of cancer: the next generation Cell 144 5 2011 646 674
39. D.S. Hong, L.S. Angelo, and R. Kurzrock Interleukin-6 and its receptor in cancer: implications for translational therapeutics Cancer 110 9 2007 1911 1928
40. S. Danese, and A. Mantovani Inflammatory bowel disease and intestinal cancer: a paradigm of the Yin-Yang interplay between inflammation and cancer Oncogene 29 23 2010 3313 3323
41. H. Knupfer, and R. Preiss Serum interleukin-6 levels in colorectal cancer patients - a summary of published results Int J Colorectal Dis 25 2 2010 135 140
42. F.M. Corvinus, C. Orth, R. Moriggl, S.A. Tsareva, S. Wagner, and E.B. Pfitzner Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth Neoplasia 7 6 2005 545 555
43. T. Morikawa, Y. Baba, M. Yamauchi, A. Kuchiba, K. Nosho, and K. Shima STAT3 expression, molecular features, inflammation patterns, and prognosis in a database of 724 colorectal cancers Clin Cancer Res 17 6 2011 1452 1462
44. S.A. Tsareva, R. Moriggl, F.M. Corvinus, B. Wiederanders, A. Schutz, and B. Kovacic Signal transducer and activator of transcription 3 activation promotes invasive growth of colon carcinomas through matrix metalloproteinase induction Neoplasia 9 4 2007 279 291
45. C. Becker, M.C. Fantini, S. Wirtz, A. Nikolaev, H.A. Lehr, and P.R. Galle IL-6 signaling promotes tumor growth in colorectal cancer Cell Cycle 4 2 2005 217 220
46. Seavey MM, Lu LD, Stump KL, Wallace NH, Hockeimer W, O'Kane T, Ruggeri BA, Dobrzanski P, Therapeutic efficacy of CEP-33779, a novel selective JAK2 inhibitor, in a mouse model of colitis-induced colorectal cancer. Mol Cancer Ther, in review.
47. F.R. Greten, L. Eckmann, T.F. Greten, J.M. Park, Z.W. Li, and L.J. Egan IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer Cell 118 3 2004 285 296
48. R.J. Rigby, J.G. Simmons, C.J. Greenhalgh, W.S. Alexander, and P.K. Lund Suppressor of cytokine signaling 3 (SOCS3) limits damage-induced crypt hyper-proliferation and inflammation-associated tumorigenesis in the colon Oncogene 26 33 2007 4833 4841
49. B.J. Jenkins, D. Grail, T. Nheu, M. Najdovska, B. Wang, and P. Waring Hyperactivation of Stat3 in gp130 mutant mice promotes gastric hyperproliferation and desensitizes TGF-beta signaling Nat Med 11 8 2005 845 852
50. M. Ernst, M. Najdovska, D. Grail, T. Lundgren-May, M. Buchert, and H. Tye STAT3 and STAT1 mediate IL-11-dependent and inflammation-associated gastric tumorigenesis in gp130 receptor mutant mice J Clin Invest 118 5 2008 1727 1738
51. L.D. Lu, K.L. Stump, N.H. Wallace, P. Dobrzanski, C. Serdikoff, and D.E. Gingrich Depletion of autoreactive plasma cells and treatment of lupus nephritis in mice using CEP-33779, a novel, orally active, selective inhibitor of JAK2 J Immunol 187 7 2011 3840 3853
52. M.A. Curry, B.J. Dugan, D.E. Gingrich, E.F. Mesaros, and K.L. Milkiewicz Preparation and uses of 1,2,4-triazolo [1,5A] pyridine derivatives 2011 Cephalon, Inc. Frazer, PA, USA p. 1-205 [Filed: June 4, 2010; Publication No: US 2010/0311693; Application No: 12/793,984]
53. L. Chen, W. Fischle, E. Verdin, and W.C. Greene Duration of nuclear NF-kappaB action regulated by reversible acetylation Science 293 5535 2001 1653 1657
54. H. Lee, A. Herrmann, J.H. Deng, M. Kujawski, G. Niu, and Z. Li Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors Cancer Cell 15 4 2009 283 293
55. S.I. Grivennikov, D.V. Kuprash, Z.G. Liu, and S.A. Nedospasov Intracellular signals and events activated by cytokines of the tumor necrosis factor superfamily: from simple paradigms to complex mechanisms Int Rev Cytol 252 2006 129 161
56. L.A. Gilbert, and M.T. Hemann DNA damage-mediated induction of a chemoresistant niche Cell 143 3 2010 355 366
57. K.L. Stump, L.D. Lu, P. Dobrzanski, C. Serdikoff, D.E. Gingrich, and B.J. Dugan A highly selective, orally active inhibitor of Janus kinase 2, CEP-33779, ablates disease in two mouse models of rheumatoid arthritis Arthritis Res Ther 13 2 2011 R68
58. J.M. Diamond, and J.V. Melo Mechanisms of resistance to BCR-ABL kinase inhibitors Leuk Lymphoma 52 Suppl. 1 2011 12 22
59. D. Solit, and C.L. Sawyers Drug discovery: how melanomas bypass new therapy Nature 468 7326 2010 902 903
60. R.A. Cairns, I.S. Harris, and T.W. Mak Regulation of cancer cell metabolism Nat Rev Cancer 11 2 2011 85 95
61. M.G. Vander Heiden Targeting cancer metabolism: a therapeutic window opens Nat Rev Drug Discov 10 9 2011 671 684
62. D.R. Wise, R.J. DeBerardinis, A. Mancuso, N. Sayed, X.Y. Zhang, and H.K. Pfeiffer Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction Proc Natl Acad Sci USA 105 48 2008 18782 18787
63. F. Weinberg, R. Hamanaka, W.W. Wheaton, S. Weinberg, J. Joseph, and M. Lopez Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity Proc Natl Acad Sci USA 107 19 2010 8788 8793
64. J.B. Wang, J.W. Erickson, R. Fuji, S. Ramachandran, P. Gao, and R. Dinavahi Targeting mitochondrial glutaminase activity inhibits oncogenic transformation Cancer Cell 18 3 2010 207 219
65. M.M. Reddy, M.S. Fernandes, A. Deshpande, E. Weisberg, H.V. Inguilizian, and O. Abdel-Wahab The JAK2V617F oncogene requires expression of inducible phosphofructokinase/fructose-bisphosphatase 3 for cell growth and increased metabolic activity Leukemia 2011
66. V. Oldfield, S. Dhillon, and G.L. Plosker Tocilizumab: a review of its use in the management of rheumatoid arthritis Drugs 69 5 2009 609 632
67. K. West CP-690550. a JAK3 inhibitor as an immunosuppressant for the treatment of rheumatoid arthritis, transplant rejection, psoriasis and other immune-mediated disorders Curr Opin Investig Drugs 10 5 2009 491 504
68. J.S. Fridman, P.A. Scherle, R. Collins, T.C. Burn, Y. Li, and J. Li Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050 J Immunol 184 9 2010 5298 5307
69. Y. Uchiyama, K. Yorozu, M. Hashizume, Y. Moriya, and M. Mihara Tocilizumab, a humanized anti-interleukin-6 receptor antibody, ameliorates joint swelling in established monkey collagen-induced arthritis Biol Pharm Bull 31 6 2008 1159 1163
70. D.P. D'Cruz, M.A. Khamashta, and G.R. Hughes Systemic lupus erythematosus Lancet 369 9561 2007 587 596
71. S. Kamphuis, and E.D. Silverman Prevalence and burden of pediatric-onset systemic lupus erythematosus Nat Rev Rheumatol 6 9 2010 538 546
72. G.J. Pons-Estel, G.S. Alarcon, L. Scofield, L. Reinlib, and G.S. Cooper Understanding the epidemiology and progression of systemic lupus erythematosus Semin Arthritis Rheum 39 4 2010 257 268
73. D. Elbirt, D. Sthoeger, I. Asher, and Z.M. Sthoeger The management of systemic lupus erythematosus: facts and controversies Clin Dermatol 28 3 2010 330 336
74. L. Morel Genetics of SLE: evidence from mouse models Nat Rev Rheumatol 6 6 2010 348 357
75. M. Aringer, and J.S. Smolen Tumour necrosis factor and other proinflammatory cytokines in systemic lupus erythematosus: a rationale for therapeutic intervention Lupus 13 5 2004 344 347
76. D.L. Smith-Bouvier, A.A. Divekar, M. Sasidhar, S. Du, S.K. Tiwari-Woodruff, and J.K. King A role for sex chromosome complement in the female bias in autoimmune disease J Exp Med 205 5 2008 1099 1108
77. H.Y. Chun, J.W. Chung, H.A. Kim, J.M. Yun, J.Y. Jeon, and Y.M. Ye Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus J Clin Immunol 27 5 2007 461 466
78. M. Tucci, L. Lombardi, H.B. Richards, F. Dammacco, and F. Silvestris Overexpression of interleukin-12 and T helper 1 predominance in lupus nephritis Clin Exp Immunol 154 2 2008 247 254
79. T.B. Niewold, J. Hua, T.J. Lehman, J.B. Harley, and M.K. Crow High serum IFN-alpha activity is a heritable risk factor for systemic lupus erythematosus Genes Immun 8 6 2007 492 502
80. O. Winter, K. Moser, E. Mohr, D. Zotos, H. Kaminski, and M. Szyska Megakaryocytes constitute a functional component of a plasma cell niche in the bone marrow Blood 116 11 2010 1867 1875
81. M. Gayed, and C. Gordon Novel treatments for systemic lupus erythematosus Curr Opin Investig Drugs 11 11 2010 1256 1264
82. R.J. Looney B cell-targeted therapies for systemic lupus erythematosus: an update on clinical trial data Drugs 70 5 2010 529 540
83. R. Voll, and F. Hiepe Depletion of plasma cells - a novel strategy in the therapy of systemic lupus erythematosus in mice and man Z Rheumatol 68 2 2009 150 153
84. K. Neubert, S. Meister, K. Moser, F. Weisel, D. Maseda, and K. Amann The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis Nat Med 14 7 2008 748 755
85. R. Han, and T.J. Smith T helper type 1 and type 2 cytokines exert divergent influence on the induction of prostaglandin E2 and hyaluronan synthesis by interleukin-1beta in orbital fibroblasts: implications for the pathogenesis of thyroid-associated ophthalmopathy Endocrinology 147 1 2006 13 19
86. C.J. Hwang, N. Afifiyan, D. Sand, V. Naik, J. Said, and S.J. Pollock Orbital fibroblasts from patients with thyroid-associated ophthalmopathy overexpress CD40: CD154 hyperinduces IL-6, IL-8, and MCP-1 Invest Ophthalmol Vis Sci 50 5 2009 2262 2268
87. H.L. Ramos, G. Valencia-Pacheco, J. Alcocer-Varela, and Constitutive STAT3 activation in peripheral CD3(+) cells from patients with primary Sjogren's syndrome Scand J Rheumatol 37 1 2008 35 39
88. G.F. Ferraccioli, D. Sorrentino, S. De Vita, L. Casatta, A. Labombarda, and C. Avellini B cell clonality in gastric lymphoid tissues of patients with Sjogren's syndrome Ann Rheum Dis 55 5 1996 311 316
89. T. Tokuno, H. Takahashi, C. Suzuki, M. Yamamoto, Y. Naishiro, and A. Sugaya Analysis of B-cell clonality in the hepatic tissue of patients with Sjogren's syndrome Scand J Rheumatol 32 5 2003 268 272
90. E. Dominguez, A. Mauborgne, J. Mallet, M. Desclaux, and M. Pohl SOCS3-mediated blockade of JAK/STAT3 signaling pathway reveals its major contribution to spinal cord neuroinflammation and mechanical allodynia after peripheral nerve injury J Neurosci 30 16 2010 5754 5766
91. E. Beurel, and R.S. Jope Differential regulation of STAT family members by glycogen synthase kinase-3 J Biol Chem 283 32 2008 21934 21944
92. S. Wu, S. Divall, G.E. Hoffman, W.W. Le, K.U. Wagner, and A. Wolfe Jak2 is necessary for neuroendocrine control of female reproduction J Neurosci 31 1 2011 184 192
93. J. Qiu, W.B. Cafferty, S.B. McMahon, and S.W. Thompson Conditioning injury-induced spinal axon regeneration requires signal transducer and activator of transcription 3 activation J Neurosci 25 7 2005 1645 1653
94. N. Couturier, F. Bucciarelli, R.N. Nurtdinov, M. Debouverie, C. Lebrun-Frenay, and G. Defer Tyrosine kinase 2 variant influences T lymphocyte polarization and multiple sclerosis susceptibility Brain 134 Pt 3 2011 693 703
95. I.L. Mero, A.R. Lorentzen, M. Ban, C. Smestad, E.G. Celius, and J.H. Aarseth A rare variant of the TYK2 gene is confirmed to be associated with multiple sclerosis Eur J Hum Genet 18 4 2010 502 504
96. M. Ban, A. Goris, A.R. Lorentzen, A. Baker, T. Mihalova, and G. Ingram Replication analysis identifies TYK2 as a multiple sclerosis susceptibility factor Eur J Hum Genet 17 10 2009 1309 1313
97. H. Wang, J. Brown, C.A. Garcia, Y. Tang, M.R. Benakanakere, and T. Greenway The role of glycogen synthase kinase 3 in regulating IFN-beta-mediated IL-10 production J Immunol 186 2 2011 675 684
98. J.J. Bright, C. Du, and S. Sriram Tyrphostin B42 inhibits IL-12-induced tyrosine phosphorylation and activation of Janus kinase-2 and prevents experimental allergic encephalomyelitis J Immunol 162 10 1999 6255 6262
99. M. Tsuda, Y. Kohro, T. Yano, T. Tsujikawa, J. Kitano, and H. Tozaki-Saitoh JAK-STAT3 pathway regulates spinal astrocyte proliferation and neuropathic pain maintenance in rats Brain 134 Pt 4 2011 1127 1139
100. J.H. Coombs, B.J. Bloom, F.C. Breedveld, M.P. Fletcher, D. Gruben, and J.M. Kremer Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial Ann Rheum Dis 69 2 2010 413 416
101. E. Dominguez, C. Rivat, B. Pommier, A. Mauborgne, and M. Pohl JAK/STAT3 pathway is activated in spinal cord microglia after peripheral nerve injury and contributes to neuropathic pain development in rat J Neurochem 107 1 2008 50 60
102. J. Wan, A.K. Fu, F.C. Ip, H.K. Ng, J. Hugon, and G. Page Tyk2/STAT3 signaling mediates beta-amyloid-induced neuronal cell death: implications in Alzheimer's disease J Neurosci 30 20 2010 6873 6881
103. Y.D. Kwak, E. Dantuma, S. Merchant, S. Bushnev, and K. Sugaya Amyloid-beta precursor protein induces glial differentiation of neural progenitor cells by activation of the IL-6/gp130 signaling pathway Neurotox Res 18 3-4 2010 328 338
104. A. Akaike, Y. Takada-Takatori, T. Kume, and Y. Izumi Mechanisms of neuroprotective effects of nicotine and acetylcholinesterase inhibitors: role of alpha4 and alpha7 receptors in neuroprotection J Mol Neurosci 40 1-2 2010 211 216
105. N. Hou, and J.D. Luo Leptin and cardiovascular diseases Clin Exp Pharmacol Physiol 2011 905 913
106. I.M. Fenyo, I.C. Florea, M. Raicu, and A. Manea Tyrphostin AG490 reduces NAPDH oxidase activity and expression in the aorta of hypercholesterolemic apolipoprotein E-deficient mice Vascul Pharmacol 54 3-6 2011 100 106
107. Z.C. Mo, J. Xiao, X.H. Liu, Y.W. Hu, X.X. Li, and G.H. Yi AOPPs inhibits cholesterol efflux by down-regulating ABCA1 expression in a JAK/STAT signaling pathway-dependent manner J Atheroscler Thromb 18 9 2011 796 807
108. R.H. Bhogal, and S.C. Afford Reply: blockade of Janus kinase 2 signaling ameliorates mouse liver damage due to ischemia and reperfusion Liver Transpl 16 12 2010 1443
109. V. De Stefano, E. Rossi, T. Za, A. Ciminello, S. Betti, and C. Luzzi JAK2 V617F mutational frequency in essential thrombocythemia associated with splanchnic or cerebral vein thrombosis Am J Hematol 86 6 2011 526 528
110. T. Kanellopoulou, A. Alexopoulou, and J. Koskinas JAK2V617F mutation is ubiquitously present in splanchnic vein thrombosis accompanying myeloproliferative syndromes Aliment Pharmacol Ther 33 12 2011 1382 1383
111. M.Y. Donath, and S.E. Shoelson Type 2 diabetes as an inflammatory disease Nat Rev Immunol 11 2 2011 98 107
112. D. Choi, S.A. Schroer, S.Y. Lu, L. Wang, X. Wu, and Y. Liu Erythropoietin protects against diabetes through direct effects on pancreatic beta cells J Exp Med 207 13 2010 2831 2842